Experimental Pancreatic Cancer Pill Extends Survival in Clinical Trial

An experimental pill improved survival rates for patients with advanced pancreatic cancer, researchers announced Sunday, offering a potential treatment option for a disease with limited therapeutic alternatives.

Scientists conducted the trial involving patients with cancer that had spread beyond the pancreas. Participants who received the medication lived longer than those in a comparison group, according to the researchers' findings.

Pancreatic cancer ranks among the most difficult cancers to treat. The disease carries a five-year survival rate of approximately 12 percent, according to the National Institutes of Health. Most patients receive a diagnosis after the cancer has progressed to advanced stages, when treatment options become more limited.

The medication works by targeting specific mechanisms that allow cancer cells to grow and spread. Researchers selected study participants based on genetic markers associated with their tumors, a strategy that allowed them to identify patients most likely to benefit from the drug.

The trial compared outcomes between patients receiving the experimental pill and those receiving standard chemotherapy. Researchers measured survival duration from the start of treatment until death from any cause.

Development of new pancreatic cancer treatments has proceeded slowly compared to other malignancies. Researchers attribute the challenge to the tumor's aggressive biology and its tendency to develop resistance to available medications.

The announcement comes as multiple drug makers pursue novel approaches to pancreatic cancer. Some focus on immunotherapy, which trains the immune system to recognize and attack cancer cells. Others target genetic mutations found in certain tumors.

Next steps for the medication include additional clinical testing to confirm the findings and to identify which patient populations benefit most. Regulatory agencies will review the data before determining whether to approve the drug for widespread use.

The research represents one of several recent efforts to expand treatment options for pancreatic cancer patients. If approved, the medication would join a limited arsenal of drugs designed specifically for advanced pancreatic disease.